Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...
One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their ...
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...
The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
LVMH has reclaimed its spot as the biggest company in Europe, overtaking Novo Nordisk after a significant drop in the ...
A study published in Nature Medicine looks at the health risks and benefits linked to GLP-1 receptor agonists. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University ...
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis ...
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...
FAT loss jabs have been spotted being flogged for £40 on TikTok as hundreds of Brits have been hospitalised with “serious ...